Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4154002

CN1CCC(C(=O)N[C@@H](CCCSCC(=O)C(F)(F)F)C(=O)NC2CCN(Cc3ccccc3)CC2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
TSHR P16473 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
SIGMAR1 Q99720 4/20 0.40
ACE P12821 1/20 0.40
UBE2M P61081 3/20 0.40
DCUN1D1 Q96GG9 3/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
KMT2A Q03164 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
CAPN1 P07384 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4606072 0.87 SIGMAR1 (0.52) SIGMAR1
Trifluoroacetic Acid SCHEMBL4164045 0.85 TSHR (0.44) CYP2C19SMN1; SMN2TSHRSIGMAR1UBE2M
Trifluoroacetic Acid SCHEMBL4159826 0.83 CCR2 (0.49) TSHRSIGMAR1UBE2MDCUN1D1KMT2A
Trifluoroacetic Acid SCHEMBL4161039 0.81 SIGMAR1 (0.57) SIGMAR1DRD2DRD4
Trifluoroacetic Acid SCHEMBL4171437 0.81 SIGMAR1 (0.47) SMN1; SMN2SIGMAR1DRD4
Trifluoroacetic Acid SCHEMBL4150100 0.80 CHRM2 (0.42) TSHRSIGMAR1UBE2MDCUN1D1DRD2
Trifluoroacetic Acid SCHEMBL4156514 0.79 SMN1; SMN2 (0.37) SMN1; SMN2ACEKMT2A
Trifluoroacetic Acid SCHEMBL4622701 0.79 CHRM1 (0.46) SIGMAR1UBE2MDCUN1D1
SCHEMBL5121666 0.79 CYP2C19 (0.53) CYP2C19SMN1; SMN2TSHRL3MBTL1SIGMAR1
Trifluoroacetic Acid SCHEMBL4154008 0.76 CHRM2 (0.38) SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054448-A1 Amino Acid Derivatives as Histone Deacetylase (HDAC) Inhibitors JONES PHILIP 2009-02-26 US disclosed
EP-1945609-A2 AMINO ACID DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2008-07-23 EP disclosed
WO-2007029036-A2 AMINO ACID DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054448-A1 Amino Acid Derivatives as Histone Deacetylase (HDAC) Inhibitors HDAC5, HDAC1, HDAC11 CYP2C19 2603/4885SMN1; SMN2 1280/4885TSHR 1377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.